Trius Antibiotic Torezolid to be Highlighted at ECCMID Meeting

SAN DIEGO, May 4, 2011 (GLOBE NEWSWIRE) — Trius Therapeutics, Inc. (Nasdaq:TSRX), announced today that the results of two studies of torezolid phosphate (TR-701) will be presented at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Milan, Italy on May 7th — 10th. Torezolid phosphate is a fast-acting, bactericidal 2nd generation IV and oral oxazolidinone.   

“Acceptance of these presentations by the ECCMID committee highlights the value of torezolid in treating gram-positive infections,” stated Philippe Prokocimer, MD, Chief Medical Officer of Trius. “We are pleased to provide details of our 2009-2010 European microbiological surveillance study showing up to 8-fold greater activity against MRSA isolates compared to linezolid. We will also report the results of a placebo-controlled Phase 1 study further demonstrating that torezolid phosphate is well tolerated when administered via a peripheral vein.”

The presentations are as follows:

Sunday, May 8th

Foyer & Exhibition (12:30 — 13:30)

P 947: Comparative in vitro potency of torezolid (TR-700) and linezolid against key gram-positive pathogens of European origin (2009-2010)

Monday, May 9th

Foyer & Exhibition (12:30 — 13:30)

P 1516: Assessment of the venous tolerability of torezolid phosphate infused via a peripheral catheter: a novel approach

Copies of these posters will be available on the Trius website following the ECCMID meeting.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The Company’s first product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus, or MRSA. In addition to the Company’s torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit

Relations Contact:

Jason Spark at Canale Communications, Inc.


Investor Relations Contact:

Stefan Loren at Westwicke Partners, LLC


CEO Interview

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.